Human Toxicity cDNA Plate Array

Drug toxicity is mainly resulted from drug metabolism. A drug may be biotransformed by drug metabolizing enzymes to toxic or nontoxic metabolites. A number of families such as P450s, UDP-glucuronosyltransferases, sulfotransferases, organic-anion transporters and multidrug resistance proteins involve in drug metabolizing processes, which catalyze the oxidation of exogenously administered drugs. The changes in expression level of these enzymes are the key factors responsible for the individual variation in drug metabolism. Signosis developed toxicity cDNA plate array to analyze the expression of 22 drug metabolism-related genes.

A. Benefits:

Based on Signosis' proprietary cDNA plate array detection technology, we developed Human toxicity cDNA plate array, which offers following benefits:

• Simple - Do the gene expression profiling as doing ELISA.

• High sensitive detection- Detected mRNA molecules are converted into multiple biotin-labeled cDNAs for sensitive detection.

• Quantitative comparison – The difference of two or more samples in gene expression can be quantitatively analyzed.

B. Principle of the technology

Signosis’ proprietary cDNA plate array is a plate-based hybridization profiling analysis for monitoring the expression of dozens of genes through reverse transcription of mRNA into cDNA. Like array analyses, total RNA is first reverse transcribed into cDNA in the presence of biotin-dUTP in the assay. Targeted genes are then specifically captured onto individual wells on a plate, instead of membranes, through a pre-coated gene-specific oligonucleotide. The captured cDNAs are further detected with streptavidin-HRP. The captured cDNAs are further detected with streptavidin-HRP. Luminescence is reported as relative light units (RLUs) on a microplate luminometer. The expression level of genes is directly proportional to the luminescent intensity.